Humacyte Inc
HUMA2.270USD
-0.010-0.44%
交易中 （美东）报价延迟15分钟
352.12M总市值
亏损市盈率 TTM
关于 Humacyte Inc 公司
Humacyte, Inc. 致力于开发和制造现成的、可普遍植入的生物工程人体组织。该公司致力于开发一系列直径和长度各异的人体无细胞血管 (HAV)。HAV 产品最初将瞄准血管修复、重建和替换市场，包括血管创伤；血液透析的房室 (AV) 通路；外周动脉疾病 (PAD)；以及冠状动脉搭桥术 (CABG)。该公司开发了一种用于制造人体组织的新范例，旨在模仿人体生理学的关键方面。该公司还致力于开发用于儿科心脏手术和细胞疗法的 HAV，包括用于治疗 1 型糖尿病的胰岛细胞移植。该公司的科学技术平台使用来自工作细胞库的原代人主动脉血管细胞，这些细胞是从供体组织中分离并冷冻保存的。
公司简介
公司代码HUMA
公司名称Humacyte Inc
上市日期Sep 22, 2020
CEODr. Laura E. Niklason, M.D., Ph.D
员工数量218
证券类型Ordinary Share
年结日Sep 22
公司地址2525 East North Carolina Highway 54
城市DURHAM
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编27713
电话19193139633
网址https://humacyte.com/
公司代码HUMA
上市日期Sep 22, 2020
CEODr. Laura E. Niklason, M.D., Ph.D
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Laura E. Niklason, M.D., Ph.D
Dr. Laura E. Niklason, M.D., Ph.D
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.39M
--
Mr. Michael T. Constantino
Mr. Michael T. Constantino
Independent Director
Independent Director
32.95K
+94.40%
Dr. Shamik J. Parikh, M.D.
Dr. Shamik J. Parikh, M.D.
Chief Medical Officer
Chief Medical Officer
7.50K
--
Mr. Dale A. Sander
Mr. Dale A. Sander
Chief Financial Officer, Chief Corporate Development Officer, Treasurer
Chief Financial Officer, Chief Corporate Development Officer, Treasurer
--
--
Mr. Max Wallace, J.D.
Mr. Max Wallace, J.D.
Independent Director
Independent Director
--
--
Gen. C. Bruce Green
Gen. C. Bruce Green
Independent Director
Independent Director
--
--
Dr. Susan Windham-Bannister, Ph.D.
Dr. Susan Windham-Bannister, Ph.D.
Independent Director
Independent Director
--
--
Dr. John P Bamforth, Ph.D.
Dr. John P Bamforth, Ph.D.
Independent Director
Independent Director
--
--
Mr. William (B.J.) Scheessele
Mr. William (B.J.) Scheessele
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Todd M. Pope
Mr. Todd M. Pope
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Laura E. Niklason, M.D., Ph.D
Dr. Laura E. Niklason, M.D., Ph.D
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.39M
--
Mr. Michael T. Constantino
Mr. Michael T. Constantino
Independent Director
Independent Director
32.95K
+94.40%
Dr. Shamik J. Parikh, M.D.
Dr. Shamik J. Parikh, M.D.
Chief Medical Officer
Chief Medical Officer
7.50K
--
Mr. Dale A. Sander
Mr. Dale A. Sander
Chief Financial Officer, Chief Corporate Development Officer, Treasurer
Chief Financial Officer, Chief Corporate Development Officer, Treasurer
--
--
Mr. Max Wallace, J.D.
Mr. Max Wallace, J.D.
Independent Director
Independent Director
--
--
Gen. C. Bruce Green
Gen. C. Bruce Green
Independent Director
Independent Director
--
--
收入明细
FY2025Q1
FY2024Q3
FY2022Q2
FY2022Q1
暂无数据
地区USD
名称
营收
占比
United States
517.00K
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Fresenius SE & Co KGaA
11.81%
Yushvaev (Gavril Abramovich)
5.76%
BlackRock Institutional Trust Company, N.A.
4.86%
The Vanguard Group, Inc.
4.24%
State Street Global Advisors (US)
2.75%
Other
70.58%
持股股东
持股股东
占比
Fresenius SE & Co KGaA
11.81%
Yushvaev (Gavril Abramovich)
5.76%
BlackRock Institutional Trust Company, N.A.
4.86%
The Vanguard Group, Inc.
4.24%
State Street Global Advisors (US)
2.75%
Other
70.58%
股东类型
持股股东
占比
Investment Advisor
17.97%
Corporation
13.25%
Hedge Fund
8.61%
Investment Advisor/Hedge Fund
7.31%
Individual Investor
6.93%
Research Firm
2.78%
Venture Capital
2.17%
Bank and Trust
1.08%
Pension Fund
0.26%
Other
39.63%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
347
93.77M
60.45%
+11.76M
2025Q1
346
95.39M
64.76%
+11.80M
2024Q4
319
75.99M
61.96%
-3.94M
2024Q3
283
71.70M
59.72%
-5.88M
2024Q2
264
68.34M
57.06%
+3.14M
2024Q1
231
61.49M
51.37%
+1.67M
2023Q4
225
55.97M
54.06%
-5.15M
2023Q3
227
54.57M
52.73%
-6.28M
2023Q2
223
56.13M
54.24%
-11.76M
2023Q1
219
61.42M
59.44%
-8.48M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fresenius SE & Co KGaA
18.31M
11.81%
--
--
May 13, 2025
Yushvaev (Gavril Abramovich)
8.94M
5.76%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.54M
4.86%
+87.54K
+1.18%
Mar 31, 2025
The Vanguard Group, Inc.
6.57M
4.24%
+990.86K
+17.74%
Mar 31, 2025
State Street Global Advisors (US)
4.27M
2.75%
-344.53K
-7.47%
Mar 31, 2025
Heights Capital Management, Inc.
4.03M
2.59%
+4.03M
--
Mar 31, 2025
Woodline Partners LP
3.95M
2.55%
+1.10M
+38.65%
Mar 31, 2025
RA Capital Management, LP
3.31M
2.14%
+3.31M
--
Mar 31, 2025
Citadel Advisors LLC
2.91M
1.88%
+2.74M
+1598.28%
Mar 31, 2025
Ayabudge LLC
2.24M
1.44%
+510.16K
+29.47%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Clough Select Equity ETF
1.88%
Hypatia Women CEO ETF
0.15%
SPDR S&P Biotech ETF
0.1%
iShares Micro-Cap ETF
0.06%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.01%
查看更多
Clough Select Equity ETF
占比1.88%
Hypatia Women CEO ETF
占比0.15%
SPDR S&P Biotech ETF
占比0.1%
iShares Micro-Cap ETF
占比0.06%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
iShares Biotechnology ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
